1. Human Disease Mouse Models {#sec1}
=============================

Model organisms such as fruit flies, zebrafish, and mice have provided great insights into gene function in humans because they are easy to grow and genetically manipulate in the laboratory setting. By evaluating different mutations in these organisms, one can identify candidate genes that lead to disease in humans and develop models to better understand human disease pathogenesis \[[@B1]\]. The mouse is an ideal model organism for human disease. Not only they are physiologically similar to humans, but a large genetic reservoir of potential models of human disease has been accumulated through the generation of radiation- or chemically induced mutant loci. Multiple technological advances have dramatically advanced our skills to create mouse models of human diseases. High-resolution genetic and physical linkage maps of the mouse genome have greatly facilitated the identification and cloning of mouse disease genes. Furthermore, transgenic approaches allowed us to ectopically express or make germline mutations in virtually any gene in the mouse genome by using homologous recombination in embryonic stem (ES) cells \[[@B2], [@B3]\]. Inbred, congenic and transgenic strains are widely used in current research labs as very valuable tools to investigate human diseases pathogenesis and develop new effective therapeutical strategies.

2. Embryonic Stem (ES) and Induced Pluripotent Stem (iPS) Cells {#sec2}
===============================================================

Pluripotency is the ability of a cell to give rise to progeny representing all types of cells in an organism \[[@B4]\]. Murine embryonic stem cells derived from inner cell mass (ICM) of the embryo exhibit two remarkable features in culture. First, under certain conditions, they can be propagated indefinitely as a stable self-renewing population where every cell undergoes symmetrical division. This immortalized phenotype allows ES cells to be cultured over extended periods of time. Upon differentiation, this feature is lost and progeny undergoes cellular aging (Hayflick limit) as has been previously documented for all other nontransformed primary cells \[[@B5]\]. A second feature is that, during culture, ES cells retain their pluripotency and can differentiate into the same range of cell types as those seen in the embryo from ICM. The value of ES cells is partly due to their amenability to extensive gene manipulation. Homologous recombination between genomic and the exogenous DNA is a very inefficient and rare process, but it takes place in ES cells with relatively higher efficiency than it does in other cell types \[[@B4]\]. Gene targeting by homologous recombination in ES cells has improved our ability to study many biological processes \[[@B3]\]. Since ES cells contribute to all tissues upon injection into a recipient blastocyst, including the germline \[[@B6], [@B7]\] modification in an ES cell genome can be transmitted, by the breeding of ES cell/wild-type chimaeras, to generate mice containing the desired mutations in all cells. In this way mice with a variety of modifications such as null and point mutations, chromosomal rearrangements and large deletions have been generated. In addition, it is possible to target reporter genes under the control of specific promoters to study gene expression patterns in different cell types. Furthermore, the ability of ES cells to differentiate in vitro to many different mature somatic cell types, in combination with purification of the cell of interest by methods such as directed differentiation and lineage selection, opens up the opportunity to use these mature cell types for various basic and therapeutical applications \[[@B3]\]. Unfortunately, not every mouse model is permissive for true ES cells derivation. This makes it harder to investigate gene function and pathogenesis in those strains. With the advent of iPS technology this issue has been overcome.

In 2006, Takahashi and Yamanaka initially reported the direct reprogramming of murine embryonic fibroblasts (MEFs) to pluripotent stem cells by introducing four transcription factors \[[@B8]\]. Those factors, namely, *Oct4*, *Sox2*, *Klf4,*and c*Myc,*that are important for self-renewal of embryonic stem cells (ESCs) have been shown to reprogram both mouse and human somatic cells into ESC-like pluripotent cells ([Figure 1](#fig1){ref-type="fig"}). Since then, a large number of laboratories have derived induced pluripotent stem cells from somatic cells, and many important advances have been made \[[@B9]--[@B15]\]. Most importantly these iPS cells have shown properties very similar to the ones of ES cells such as pluripotency markers expression, teratoma formation, chimeras contribution, and germline transmission. Moreover, the critical advantages of iPS cells over ES cells now seem to be obvious. First of all iPS cells are being generated from the autologous recipient thus obviating the graft-versus-host problem in transplantation settings. The second benefit pertains to the ethical concerns. Unlike in the past, one can now generate ES-like iPS cells from human skin fibroblasts or hair-follicle cells without the need to resort to the human ES cell lines and potentially (in the future) apply them to the therapeutic and/or basic science approaches \[[@B13]\].

3. Making Use of iPS Cells for Human Disease Modeling {#sec3}
=====================================================

For the human disease animal modeling iPS cell technology opened the way to even wider spectrum of available mouse model strains. In 2009, Zhao et al. reported the generation of all-iPS-derived viable, fertile live-born progeny by tetraploid complementation \[[@B16]\] which further proved them to be useful for the development of transgenic mice strains with desired gene defects homologous to those seen in human pathology.

At present, with this valuable tool in hand one can take literally any human disease mouse strain somatic cells (e.g., tail tip fibroblasts) and induce pluripotent stem cells from them. These disease-specific iPS cells can be further used to explore given disease mechanisms both in vitro and in vivo. ([Figure 2](#fig2){ref-type="fig"}). For example, human chronic lymphocytic leukemia (CLL) (CD5+ B-cell malignancy) mouse model---New Zealand Black mouse---exhibits a defect in the miR-15a/16--1 gene on chromosome 14 which results in decreased levels of these microRNAs, which is also seen in more than 50% of CLL patients \[[@B17]\]. Unfortunately, this mouse strain is refractory to true ES cells derivation which makes it difficult to study the role of this microRNA gene defect in B-cell development both in vitro and in vivo. In our lab, we were able to successfully generate NZB iPS cells from spleen stromal cells. Now they can be used as subjects for gene targeting (correcting miR-15a/16--1 mutation and deletion) followed by in vitro differentiation towards B-lineage. This would help find out what role this particular gene defect plays in B-cell lymphogenesis and how its correction might alleviate malignant clonal expansion. Furthermore, NZB iPS cells with corrected miR-15a defect could be differentiated into hematopoietic stem cells (HSCs) followed by their adoptive transfer into appropriate recipients in order to observe the effect of gene correction on CLL development in vivo.

Another way to utilize iPS cells to study human diseases in animal models is xenograft transplantation assay. In this case iPS cells would be generated from patient\'s somatic cells ([Figure 3](#fig3){ref-type="fig"}), differentiated into desired type of cells (e.g., HSC), and transplanted into immunodeficient murine recipients. In a recent report, Yao et al. \[[@B18]\] have demonstrated a generation of human iPS cells with zinc-finger nuclease, mediated disruption of CCR5 locus which is known to be a coreceptor for HIV entry. These patient-specific iPS cells can now be differentiated into HSC and transplanted into animal recipients to study the role of CCR5 in HIV infection development in vivo. In another work, Lee et al. have used human iPS-derived neural stem cells (NSCs) in a mouse intracranial human glioma xenograft model \[[@B19]\]. In this case, iPS-derived NSCs have been used as cellular vehicles for targeted anticancer gene therapy since they will home to the brain. As a proof of principle, Hanna and colleagues have taken advantage of autologous iPS cells derived from humanized mouse model of sickle cells anemia to correct human sickle hemoglobin allele by gene-specific targeting followed by their differentiation into hematopoietic stem cells and transplantation into irradiated recipients \[[@B20]\]. It has been shown that mice could be rescued from disease progression after transplantation. This work has underlined the benefits of iPS technology for the combined gene and cell therapy approach to study human disease in animal models. It is needless to say that currently various labs worldwide use patient-specific iPS cells for animal modeling both in vitro and in vivo. Such pathological conditions as Huntington disease, amyotrophic lateral sclerosis, spinal muscular dystrophy, Gaucher disease type III, Down syndrome, type 1 diabetes, Parkinson\'s disease, *β*-thalassemia, and hepatic failure have been investigated using iPS cells generation \[[@B20]--[@B29]\].

4. MicroRNAs {#sec4}
============

MicroRNAs (miRs) are small noncoding RNAs which are known to be critical for the expression control of more than a third of all protein coding genes \[[@B30]\] by means of binding to the 3′ untranslated region (UTR) of target mRNAs via an imperfect match to repress their translation and/or stability \[[@B31]\]. They have been implicated in the regulation of many biological processes, including the stem cells self-renewal and pluripotency \[[@B32]--[@B34]\]. MiRNAs are generated from precursor transcripts---primary miRNAs (pri-miRNAs)---that are first processed in the nucleus into an intermediate pre-miRNAs by the complex of enzymes containing Drosha and DGCR8 proteins \[[@B35]--[@B37]\]. The pre-miRNAs are then transported by the exportin 5-RanGTP shuttle into the cytoplasm, in which they are further processed by Dicer, into mature miRNAs \[[@B38]\]. In ES cells a set of microRNAs (including miR-302 and miR-17--92 clusters) closely interfere with the key pluripotency factors such as Oct4, Sox2, and Nanog \[[@B39], [@B40]\] thereby preventing them from differentiation and controlling their proper self-renewal potential \[[@B41]\]. Xu et al. have demonstrated miR-145 to control the expression of Oct4, Sox2, and Klf4 and repress self-renewal of human ES cells \[[@B42]\]. On the other hand, c-Myc has been reported to repress miRNAs such as miR-21, let-7a, and miR-29a during reprogramming \[[@B43]\]. Tissue-specific miRNAs often play important roles in normal tissues and organ formation \[[@B44], [@B45]\]. More importantly for the current review, microRNAs proved to be effective tools for the iPS generation. In particular, inhibition of miR-21, let-7a, or mir-29a has been shown to enhance the reprogramming efficiency \[[@B43]\]. Alternatively, overexpression of the miR302/367 cluster has been shown to rapidly and efficiently reprogram both mouse and human somatic cells to iPS state without any exogenous transcription factors delivery through Oct4 gene expression activation and the suppression of Hdac2 \[[@B46]\]. MicroRNA gene expression profiling in human ES cells revealed specific miR-signatures of elevated expression of miR-302 cluster, miR-200 family members as well as miR-520 cluster \[[@B47]\]. This might imply the possibility of them to be used as tools to increase the efficiency of iPS generation without any exogenous interventions into the genomic DNA of the host cells and serve as additional iPS quality control markers. Conversely, as the regulators of gene expression microRNAs could be used to drive patient-specific iPS cells down the specific cells lineage in vitro in order to produce the required cell type to be studied \[[@B48]\].

Another promise that microRNAs are holding is the development of microRNA-based gene targeting for the temporal gene-of-interest silencing \[[@B49]\]. For instance, aberrant expression of Pax5 (also known as BSAP), a critical regulator of B-cell development, is known to correlate with aggressive subsets of B-cell non-Hodgkin lymphoma \[[@B50]\]. It has been previously shown that overexpression of miR-15a/16 reduces endogenous c-Myb levels and compromises Pax5 function \[[@B51]\]. Now one can produce iPS cells from Pax5-affected non-Hodgkin lymphoma patient and apply in vitro B-cell differentiation protocol along with miR-15a/16--1 delivery to evaluate lymphomagenesis in the mouse xenograft model. Potentially, the similar approach could be employed for the discovery of leukemia (or more commonly cancer) stem cells \[[@B52]\]. Finally, miRs can be used as biomarkers of human disease progression in mouse model settings. Overall diagram of microRNA application for mouse modeling is shown in [Figure 4](#fig4){ref-type="fig"}.

5. Conclusion {#sec5}
=============

The importance of disease mouse models and their impact on medical research is hard to overestimate. Therefore the value of animal modeling is very critical for our understanding of human disease and development of new effective approaches to therapy. Induced pluripotent stem cells hold a great promise for both basic and applied science and open the road for many more opportunities for human disease research. Coupled with the use of fine-tune regulators of gene expression, microRNAs, and mouse modeling they have a promising potential for subsequent discoveries and new therapies development in the complex field of human pathology.
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